Novartis AG's hopes of Kymriah becoming a blockbuster soon have taken a knock following the failure of the CAR-T therapy in a late-stage non-Hodgkin lymphoma (NHL) trial which could see the drug slip further behind Gilead Sciences, Inc.'s rival treatment Yescarta on the sales front.
The Swiss major has announced a disappointing update on the Phase III BELINDA study investigating Kymriah (tisagenlecleucel) in aggressive B-cell...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)